Mylan gets tentative FDA OK for generic of AIDS drug Viread

martedì 4 dicembre 2007 14:58

Dec 4 (Reuters) - Drugmaker Mylan Inc MYL.N said India-based Matrix Laboratories Ltd MAXL.BO, which is majority controlled by Mylan, received tentative U.S. regulatory approval to market the generic version of Gilead Sciences Inc's (GILD.O: Quotazione) AIDS drug Viread.

The U.S. Food and Drug Administration tentatively approved tenofovir disoproxil fumarate tablets (300 mg) under the President's Emergency Plan for AIDS Relief, the company said in a statement. (Reporting by Neha Pathania in Bangalore; Editing by Pratish Narayanan)